Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1998-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.64.5.577PMID 9598669PMCID PMC2170071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.

  1997cited by this paper
• The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A

  1997cited by this paper
• Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm

  1995cited by this paper
• Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

  1995cited by this paper
• Serial neurophysiological studies of intramuscular botulinum‐A toxin in humans

  1994cited by this paper
• Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A

  1993cited by this paper
• Therapeutic use of type F botulinum toxin.

  1992cited by this paper
• Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.

  1985cited by this paper

• Structural Basis of Botulinum Toxin Type F Binding to Glycosylated Human SV2A: In Silico Studies at the Periphery of a Lipid Raft

  2022cites this paper
• Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins

  2021cites this paper
• A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm

  2021cites this paper
• Clinical duration of action of different botulinum toxin types in humans.

  2020cites this paper
• Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

  2019cites this paper
• Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity

  2018cites this paper
• The Expanding Therapeutic Utility of Botulinum Neurotoxins

  2018cites this paper
• Immunological aspects of botulinum toxin therapy

  2017cites this paper
• Too Much of a Good Thing: Weakness, Dysphagia, and Stridor After Botulinum Toxin Injections

  2016cites this paper
• Botulinum Toxin Treatment of Cervical Dystonia

  2016cites this paper
• Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing

  2015cites this paper
• Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders

  2014cites this paper
• Effect of the Refrigerator Storage Time on the Potency of Botox for Human Extensor Digitorum Brevis Muscle Paralysis

  2013cites this paper
• Botulinum toxins: mechanisms of action, antinociception and clinical applications.

  2013cites this paper
• Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

  2012cites this paper
• BOTULINUM TOXIN

  2010cites this paper
• International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments – introduction

  2010cites this paper
• 2 – Aspectos generales de la aplicación de la toxina botulínica

  2010cites this paper
• Chapter 6 – Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins

  2009cites this paper
• Therapeutic Application of Botulinum Toxin in Clinical Practice

  2009cites this paper
• Upper Motor Neurone Syndrome and Spasticity: Spasticity and botulinum toxin

  2008cites this paper
• Role of botulinum toxin in the treatment of cervical dystonia.

  2008cites this paper
• Botulinum toxin type A in the treatment of patients with cervical dystonia

  2008cites this paper
• Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.

  2008cites this paper
• Comparative electrophysiological study of response to botulinum toxin type B in Japanese and Caucasians

  2008cites this paper
• Botulinum Toxin for Lower Urinary Tract Symptoms in Women

  2008cites this paper
• Clinical Use of Non-A Botulinum Toxins: Botulinum Toxin Type C and Botulinum Toxin Type F

  2006cites this paper
• Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F

  2006cites this paper
• Botulinum Toxins: Transformation of a Toxin into a Treatment

  2005cites this paper
• Botulinum Neurotoxins: Origins and Basic Mechanisms of Action

  2004cites this paper
• Botulinum toxins in neurological disease

  2004cites this paper
• Botulinum toxin: a successful therapeutic protein.

  2004cites this paper
• Treatment of cervical dystonia with botulinum toxin

  2004cites this paper
• Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy

  2004cites this paper
• Treatment of cervical dystonia with botulinum toxin

  2004cites this paper
• [Antibody-induced failure of botulinum toxin therapy].

  2003cites this paper
• Antikörpervermitteltes Versagen der Botulinum-Toxin-Therapie

  2003cites this paper
• Uso de la toxina botulínica en dermatología, ¿todo son éxitos?

  2002cites this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cites this paper
• Extensor digitorum brevis test and resistance to botulinum toxin type A

  2002cites this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cites this paper
• Botulinum toxin type B (Myobloc™, NeuroBloc™): a new choice in cervical dystonia

  2001cites this paper
• The Botulinum Toxins in the Treatment of Cervical Dystonia

  2001cites this paper
• Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

  2001cites this paper
• [Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes].

  2001cites this paper
• Botulinum-Toxin A in der Therapie von Kopfschmerzerkrankungen und perikranialen Schmerzsyndromen

  2001cites this paper
• The current status and use of botulinum toxins

  2001cites this paper
• Pharmacology and immunology of botulinum toxin serotypes

  2001cites this paper
• Uses of botulinum toxin injection in medicine today

  2000cites this paper
• The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.

  2000cites this paper
• Surgery for Spasmodic Torticollis

  2000cites this paper
• Botulinum toxin and spasticity

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• Pharmacotherapy with Botulinum Toxin: Harnessing Nature's Most Potent Neurotoxin

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer's disease

  2000cites this paper
• Preoperative use of enoxaparin and tirofiban: possible association with increased bleeding postbypass.

  1999cites this paper
• Postpartum subdural hygroma after epidural analgesia.

  1999cites this paper
• Botulinum toxin: issues and applications

  1999cites this paper
• Combined use of type A and F botulinum toxins for blepharospasm: A double‐blind controlled trial

  1999cites this paper
• [Treatment of dystonias].

  1999cites this paper
• Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

  1999cites this paper
• Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin.

  1999cites this paper
• The current status of tardive dystonia.

  1999cites this paper
• Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

  1999cites this paper
• The role of botulinus toxin type A in treatment--with special reference to children.

  1999cites this paper
• Botulinum toxin in motor disorders.

  1999cites this paper
• Postpartum Subdural Hygroma after Epidural Analgesia

  1999cites this paper